NCT04184414View on ClinicalTrials.gov

The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 9, 2018

Primary Completion Date

January 1, 2020

Study Completion Date

January 1, 2020

Conditions
B Acute Lymphoblastic LeukemiaMantle Cell LymphomaFollicular Lymphoma
Interventions
DRUG

CD19-CART

1-10x106 / kg CD19 CART cells

Trial Locations (1)

Unknown

RECRUITING

Hematology Department of the Second Affiliated Hospital of Suzhou University, Suzhou

Sponsors
All Listed Sponsors
collaborator

Second Affiliated Hospital of Suzhou University

OTHER

lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY